219 related articles for article (PubMed ID: 19167478)
1. Chronic nicotine alters cannabinoid-mediated locomotor activity and receptor density in periadolescent but not adult male rats.
Werling LL; Reed SC; Wade D; Izenwasser S
Int J Dev Neurosci; 2009 May; 27(3):263-9. PubMed ID: 19167478
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic nicotine exposure on Δ
Miladinovic T; Manwell LA; Raaphorst E; Malecki SL; Rana SA; Mallet PE
Pharmacol Biochem Behav; 2020 Jul; 194():172931. PubMed ID: 32353393
[TBL] [Abstract][Full Text] [Related]
3. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
4. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats.
Norwood CS; Cornish JL; Mallet PE; McGregor IS
Eur J Pharmacol; 2003 Mar; 465(1-2):105-14. PubMed ID: 12650839
[TBL] [Abstract][Full Text] [Related]
5. Chronic nicotine exposure attenuates the effects of Δ
Manwell LA; Miladinovic T; Raaphorst E; Rana S; Malecki S; Mallet PE
Brain Behav; 2019 Nov; 9(11):e01375. PubMed ID: 31583843
[TBL] [Abstract][Full Text] [Related]
6. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
8. Pre-conception exposure to THC fails to impact nicotine reward in adult offspring.
Hempel BJ; Melkumyan M; Crissman ME; Winston CA; Madar J; Riley AL
Pharmacol Biochem Behav; 2020 Oct; 197():173001. PubMed ID: 32710886
[TBL] [Abstract][Full Text] [Related]
9. Nicotine treatment produces persistent increases in amphetamine-stimulated locomotor activity in periadolescent male but not female or adult male rats.
Collins SL; Montano R; Izenwasser S
Brain Res Dev Brain Res; 2004 Nov; 153(2):175-87. PubMed ID: 15527885
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
[TBL] [Abstract][Full Text] [Related]
11. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.
Wiley JL; Barrett RL; Lowe J; Balster RL; Martin BR
Neuropharmacology; 1995 Jun; 34(6):669-76. PubMed ID: 7566504
[TBL] [Abstract][Full Text] [Related]
12. Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats.
Kelsey JE; Calabro S
Psychopharmacology (Berl); 2008 Jul; 198(4):461-6. PubMed ID: 17805516
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.
Wiley JL; Compton DR; Gordon PM; Siegel C; Singer M; Dutta A; Lichtman AH; Balster RL; Razdan RK; Martin BR
Neuropharmacology; 1996; 35(12):1793-804. PubMed ID: 9076759
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
17. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
Lichtman AH; Martin BR
Pharmacol Biochem Behav; 1997; 57(1-2):7-12. PubMed ID: 9164547
[TBL] [Abstract][Full Text] [Related]
18. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.
Solinas M; Scherma M; Tanda G; Wertheim CE; Fratta W; Goldberg SR
J Pharmacol Exp Ther; 2007 Jun; 321(3):1127-34. PubMed ID: 17351107
[TBL] [Abstract][Full Text] [Related]
19. Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Delta-9-tetrahydrocannabinol in rats.
Le Foll B; Wiggins M; Goldberg SR
Behav Pharmacol; 2006 Mar; 17(2):195-9. PubMed ID: 16495727
[TBL] [Abstract][Full Text] [Related]
20. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
